Loading…
Capricor Therapeutics, Inc. is projected to rise to $4.97 by 2027, a +29% move from its current price of $3.85. CAPR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $3.50 | $3.85 | $4.23 | -0.04% |
| Aug 4 | $3.36 | $3.85 | $4.40 | -0.09% |
| Aug 5 | $3.26 | $3.84 | $4.54 | -0.13% |
| Aug 6 | $3.18 | $3.84 | $4.65 | -0.18% |
| Aug 7 | $3.10 | $3.84 | $4.75 | -0.22% |
| Aug 8 | $3.04 | $3.84 | $4.85 | -0.27% |
| Aug 9 | $2.98 | $3.84 | $4.94 | -0.31% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.98 | $3.84 | $4.94 | -0.31% |
| Week 2 | $2.68 | $3.83 | $5.47 | -0.63% |
| Week 3 | $2.46 | $3.81 | $5.90 | -0.94% |
| Week 4 | $2.30 | $3.80 | $6.30 | -1.25% |
| Week 5 | $2.16 | $3.79 | $6.66 | -1.56% |
| Week 6 | $2.04 | $3.78 | $7.01 | -1.87% |
| Week 7 | $1.93 | $3.77 | $7.34 | -2.17% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company that engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform.
The company was founded in 2005 and is headquartered in San Diego, California.
Capricor Therapeutics, Inc. (CAPR) is a biotechnology company trading at $3.85 per share with a market cap of $222.96M, ranking 3690. The current price and market position are complemented by a multi-year forecast that shows incremental upside in several years and stronger upside later in the horizon.
The forecast data provide year-by-year targets, with notable acceleration in the 2030s and into the 2040s and 2050s.
A major floor 0.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 689.6% above — a clean break opens room to run.
A major ceiling 919.5% above — clearing it would confirm fresh momentum.
Key CAPR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CAPR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.64 | Sell | $6.89 | Sell |
| MA 10 | $12.59 | Sell | $10.74 | Sell |
| MA 20 | $16.85 | Sell | $15.25 | Sell |
| MA 50 | $23.14 | Sell | $21.18 | Sell |
| MA 100 | $27.53 | Sell | $23.79 | Sell |
| MA 200 | $23.28 | Sell | $22.56 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 11.37 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -154.57 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -1.55 | Sell |
| ROC (12) | -81.08 | Sell |
| Bollinger %B (20,2) | 0.01 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -2.13 | Sell |
| Awesome (5,34) | -15.29 | Sell |
| Ultimate (7,14,28) | 7.02 | Buy |
| Momentum (10) | -15.59 | Sell |
| Aroon Osc (25) | -100.00 | Sell |
| Hull MA (9) | 1.31 | Buy |
| ADX (14) | 46.35 | Sell |
| ATR (14) | 1.33 | Info |
Technical picture for the near term shows sentiment at NEUTRAL. The RSI(14) is 10, indicating potential oversold conditions. The 50-day simple moving average (SMA50) is $23.14 and the 200-day simple moving average (SMA200) is $23.28.
A key near-term support level sits at $3.85, with resistance at $30.40. The thirty-day price range spans from $2.05 to $7.22, reflecting notable intramonth volatility. Annualized volatility is high at 200%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.85 | $3.85 | $5.30 | 0% | Neutral | |
| $3.62 | $4.97 | $7.38 | +29% | Bullish | |
| $3.90 | $5.69 | $9.01 | +48% | Bullish | |
| $3.08 | $4.74 | $7.89 | +23% | Bullish | |
| $2.66 | $4.29 | $7.42 | +11% | Neutral | |
| $2.53 | $4.27 | $7.67 | +11% | Neutral | |
| $2.72 | $4.79 | $8.86 | +24% | Bullish | |
| $3.43 | $6.28 | $11.94 | +63% | Bullish | |
| $3.31 | $6.31 | $12.30 | +64% | Bullish | |
| $3.15 | $6.25 | $12.46 | +62% | Bullish | |
| $4.00 | $8.90 | $19.52 | +131% | Bullish | |
| $4.38 | $9.74 | $22.39 | +153% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.85 | $3.85 | $4.92 | +0.00% |
| September 2026 | $3.06 | $3.73 | $4.73 | -3.22% |
| October 2026 | $3.00 | $3.70 | $4.79 | -0.82% |
| November 2026 | $3.18 | $3.96 | $5.22 | +7.22% |
| December 2026 | $3.15 | $3.97 | $5.30 | +0.18% |
Click any year to see its month-by-month CAPR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CAPR price prediction for 2026 points to an average of $3.85 (low $3.85, high $5.30) — a potential gain of 0% on today's $3.85. A consolidation phase looks the most probable path here.
In 2027, CAPR is projected to trade between $3.62 and $7.38, averaging $4.97 — a potential gain of +29% from today's $3.85. That is up +29% on the projected 2026 average. Momentum favours further upside here.
Capricor Therapeutics, Inc.'s 2028 outlook centres on $5.69, within a $3.90 to $9.01 range. That is up +14% on the projected 2027 average. That marks a +48% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, CAPR could reach as high as $7.89, with a base case around $4.74 and support toward $3.08 — roughly +23% from $3.85. Momentum favours further upside here.
Expect CAPR to range from $2.66 to $7.42 through 2030. The $4.29 average target implies a +11% move from current prices. That is -10% versus the projected 2029 average. A consolidation phase looks the most probable path here.
The CAPR price prediction for 2031 points to an average of $4.27 (low $2.53, high $7.67) — a potential gain of +11% on today's $3.85. Price action looks broadly range-bound.
In 2032, CAPR is projected to trade between $2.72 and $8.86, averaging $4.79 — a potential gain of +24% from today's $3.85. That is up +12% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Capricor Therapeutics, Inc.'s 2033 outlook centres on $6.28, within a $3.43 to $11.94 range. That is up +31% on the projected 2032 average. That marks a +63% change versus current levels. Momentum favours further upside here.
By 2034, CAPR could reach as high as $12.30, with a base case around $6.31 and support toward $3.31 — roughly +64% from $3.85. Buyers look set to stay in control over this stretch.
Expect CAPR to range from $3.15 to $12.46 through 2035. The $6.25 average target implies a +62% move from current prices. That is -1% versus the projected 2034 average. Momentum favours further upside here.
The CAPR price prediction for 2040 points to an average of $8.90 (low $4.00, high $19.52) — a potential gain of +131% on today's $3.85. Buyers look set to stay in control over this stretch.
In 2050, CAPR is projected to trade between $4.38 and $22.39, averaging $9.74 — a potential gain of +153% from today's $3.85. That is up +9% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in CAPR today (≈ 259.74026 CAPR) could be worth
$2,528.99
+$1,528.99 (+153%) by 2050 · US Dollar
Based on the average projected CAPR price of $9.74 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CAPRwould be worth at today's price.
$1,000 invested in CAPR on Jul 31, 2025 (≈ 122.249384 CAPR) would be worth
$470.66
-$529.34 (-52.9%) today · 0.47× · US Dollar
Based on a CAPR entry price of $8.18 vs. today's $3.85.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $19.7 | $195.43 | -80.5% |
| 1 month ago | $23.07 | $166.88 | -83.3% |
| 3 months ago | $30.91 | $124.56 | -87.5% |
| 6 months ago | $23.09 | $166.74 | -83.3% |
| 1 year ago | $8.18 | $470.66 | -52.9% |
| All time (5.0y) ago | $4.45 | $865.17 | -13.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CAPR forecast.
Our base-case forecast reaches $7.70 around 2040.
Implied market cap at $7.70: $445.92M
The multi-year forecast presents a path of upside with varying momentum across years. In 2026 the min/avg/max are $3.85/$3.85/$5.30, with ROI of 0 and a NEUTRAL sentiment. From 2027 onward, the averages rise to $4.97 (avg) with a max of $7.38, ROI 29.2 and a BULLISH stance, followed by higher targets such as 2028 avg $5.69, max $9.01 (ROI 47.8, BULLISH) and 2033–2035 where the avg prices reach $6.28, $6.31, and $6.25 with max values of $11.94, $12.30, and $12.46 and ROIs of 63.1, 63.9, and 62.2 respectively.
The forecast extends to 2040 with avg $8.90, max $19.52 (ROI 131.2, BULLISH) and 2050 with avg $9.74, max $22.39 (ROI 152.9, BULLISH). These projections imply meaningful upside potential in certain years, but also periods of limited gain or decline. The annualized volatility of roughly 200% underscores substantial risk and price dispersion.
These are estimates, not guarantees, and actual results can vary.
Tap a question to reveal the answer.
The 2030 forecast shows min $2.66, avg $4.29, max $7.42 with ROI 11.3 and sentiment NEUTRAL.
The forecast indicates upside potential in several years (e.g., 2027–2035 and beyond) with max prices up to $22.39 by 2050 and ROIs as high as 152.9, but also periods with limited gains (e.g., 2026 ROI 0) and a high volatility environment (annualized volatility of 200%). These are estimates, not guarantees.
No. The highest max values in the provided forecast reach $22.39 (2050). There is no year with a max price of $30 in the given data.
Current price is $3.85. The 30-day range is $2.05 to $7.22.
Market cap is $222.96M and the rank is 3690.
Capricor Therapeutics, Inc. Community Discussion
0Share your Capricor Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.